Evidence map›Paper›PMID 35423573›Full record

ArticleRSC advances2021

A dual-functional nanovehicle with fluorescent tracking and its targeted killing effects on hepatocellular carcinoma cells.

Xiaojie Zhang, Qiming Gao, Qianfen Zhuang, Lu Zhang, Sihan Wang, Libo Du, Wenxi Yuan, Caifang Wang, Qiu Tian, Hua Yu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Xiaojie ZhangDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University Beijing P.R. China yumingzhao@ccmu.edu.cn.
Qiming GaoDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University Beijing P.R. China yumingzhao@ccmu.edu.cn.
Qianfen ZhuangState Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences 100190 Beijing P. R. China.
Lu ZhangSchool of Biomedical Engineering, Capital Medical University Beijing China.
Sihan WangDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University Beijing P.R. China yumingzhao@ccmu.edu.cn.
Libo DuState Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences 100190 Beijing P. R. China.ORCID https://orcid.org/0000-0002-1715-8352
Wenxi YuanSchool of Pharmaceutical Sciences, Capital Medical University Beijing P. R. China.
Caifang WangSchool of Pharmaceutical Sciences, Capital Medical University Beijing P. R. China.
Qiu TianState Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences 100190 Beijing P. R. China.
Hua YuInstitute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau Macao P. R. China.
Yuming ZhaoDepartment of Pharmacology, School of Basic Medical Sciences, Capital Medical University Beijing P.R. China yumingzhao@ccmu.edu.cn.ORCID https://orcid.org/0000-0002-1632-4646
Yang LiuState Key Laboratory for Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences 100190 Beijing P. R. China.
Capital University · USChinese Academy of Sciences · CNUniversity of Macau · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All-in-one drug delivery nanovehicles with low cytotoxicity, high clinical imaging tracking capability, and targeted- and controlled-releasing performances are regarded as promising nanoplatforms for tumor theranostics. Recently, the design of these novel nanovehicles by low molecular weight amphiphilic chitosan (CS) was proposed. Based on fluorescent gold nanoclusters (AuNCs), a tumor-targeting nanovehicle (

Identifiers

PMID35423573
PMCPMC8695887
OpenAlexW3135994026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.